EMA:TSXEmera Incorporated Analysis
Data as of 2026-03-13 - not real-time
CA$73.17
Latest Price
4/10Risk
Risk Level: Medium
Executive Summary
Emera is trading at C$73.17, essentially at its 52‑week high and comfortably above its 20‑day (C$70.75), 50‑day (C$68.98) and 200‑day (C$66.13) moving averages, confirming a bullish technical backdrop. The RSI sits at 71, signaling an overbought condition, while the MACD remains bullish with a modest histogram expansion. Volume is on a downtrend and beta is slightly negative (‑0.21), suggesting limited market‑wide sensitivity, yet 30‑day volatility is elevated at roughly 17%. The dividend yield is attractive at 4% but the payout ratio of 86% together with negative free cash flow (‑C$1.9 bn) and a debt‑to‑equity ratio above 160% raise sustainability questions.
Recent earnings highlighted record net income and a historic C$3.6 bn capex program, prompting analysts to diverge: some lift price targets toward C$74‑75, while others, citing valuation and regulatory headwinds, remain cautious around the C$69‑70 range. The DCF‑derived fair value of roughly C$31.8 implies the stock is significantly overvalued, and regulatory risk inherent to the utilities sector adds a medium‑high overlay. Given the strong dividend, stable regulated cash flows, but concerning leverage and valuation, a prudent stance is to hold while monitoring earnings, debt reduction progress, and any regulatory developments.
Recent earnings highlighted record net income and a historic C$3.6 bn capex program, prompting analysts to diverge: some lift price targets toward C$74‑75, while others, citing valuation and regulatory headwinds, remain cautious around the C$69‑70 range. The DCF‑derived fair value of roughly C$31.8 implies the stock is significantly overvalued, and regulatory risk inherent to the utilities sector adds a medium‑high overlay. Given the strong dividend, stable regulated cash flows, but concerning leverage and valuation, a prudent stance is to hold while monitoring earnings, debt reduction progress, and any regulatory developments.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- RSI overbought and price near resistance
- High dividend yield but sustainability concerns
- Negative free cash flow and elevated leverage
Medium Term
1–3 yearsNeutral
Model confidence: 5/10
Key Factors
- Analyst split on price targets (C$69‑75)
- Regulatory risk affecting rate growth
- Potential debt reduction from cash flow improvements
Long Term
> 3 yearsNeutral
Model confidence: 5/10
Key Factors
- Stable regulated earnings and infrastructure assets
- Long‑term dividend appeal despite payout ratio
- High debt load requiring disciplined capital allocation
Key Metrics & Analysis
Financial Health
Revenue Growth13.80%
Profit Margin12.41%
P/E Ratio21.6
ROE8.17%
ROA2.96%
Debt/Equity161.12
P/B Ratio1.8
Op. Cash FlowCA$1.8B
Free Cash FlowCA$-1922875008
Industry P/E23.3
Technical Analysis
TrendBullish
RSI71.3
SupportCA$68.68
ResistanceCA$73.39
MA 20CA$70.75
MA 50CA$68.98
MA 200CA$66.13
MACDBullish
VolumeDecreasing
Fear & Greed Index72.25
Valuation
Fair ValueCA$31.77
Target PriceCA$69.82
Upside/Downside-4.58%
GradeOvervalued
TypeBlend
Dividend Yield4.02%
Risk Assessment
Beta-0.21
Volatility17.36%
Sector RiskLow
Reg. RiskHigh
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.